By Sandy Rainford, Consultancy Director
For many pharmaceutical manufacturers, sustainability is no longer about setting ambitious targets – those ambitions already exist. The real challenge is turning them into measurable operational outcomes.
Across the industry, organisations have been investing heavily in carbon reporting, supplier engagement, Scope 3 data and ESG compliance. But in recent months we’ve noticed a significant shift: from simply reporting data to actively using it to drive the impact Sustainability Leaders and Manufacturing Directors have long been striving for. The most forward-thinking leaders are increasingly asking the more important question: how do we turn sustainability information into better business decisions? That is where the next phase of pharma sustainability will be won. The organisations that gain competitive advantage will not necessarily be those with the most comprehensive sustainability reports. They will be the ones that embed sustainability into everyday operational and strategic decision-making. But…
You can’t improve what you can’t see
One of the biggest barriers to pharmaceutical sustainability is not ambition – it’s visibility. Manufacturers often have sustainability data spread across multiple systems, suppliers and business functions. Carbon data, procurement information, manufacturing metrics and supply chain information frequently exist in isolation. As a result, leaders struggle to answer fundamental questions with confidence. Where are our biggest environmental impacts? Which suppliers create the highest carbon footprint? Which manufacturing processes should we improve first? And where will investment deliver the greatest environmental and commercial return? Without trusted, connected information, sustainability remains difficult to operationalise.
This is remarkably similar to the operational excellence challenges pharmaceutical manufacturers have spent decades solving. Improvements in quality, productivity and compliance were never achieved simply by collecting more information. They came from connecting data, creating visibility and enabling confident decision-making. Sustainability is following the same path.
Many organisations are becoming increasingly effective at collecting sustainability data. But data collection is not the objective – its real value lies in helping leaders make better decisions before resources are committed. Should production be moved between manufacturing sites? Which supplier delivers the lowest environmental impact while maintaining supply resilience? Which investment reduces emissions and operating costs? Which process improvement offers the greatest long-term value?
These are not simply sustainability questions. They are business questions with sustainability consequences. The pharmaceutical organisations creating the greatest value are therefore moving beyond retrospective reporting towards decision support – shifting the conversation from “What happened?” to “What should we do next?”
The most Sustainable Strategies don’t treat Sustainability as a trade-off
One of the biggest misconceptions surrounding sustainability is that organisations must choose between commercial performance and environmental performance. In reality, the strongest manufacturing businesses improve both simultaneously – reducing waste lowers cost, improving process efficiency reduces energy consumption, optimising supply chains can strengthen resilience while lowering emissions. The relationship is not competitive, it’s complementary.
The organisations making the greatest progress are those that stop positioning sustainability as a separate initiative and instead integrate it into operational excellence, manufacturing performance and strategic investment decisions. When sustainability becomes part of everyday business thinking, better outcomes naturally follow.
And it’s the Leadership of this that creates lasting change…
Every pharmaceutical company now has sustainability specialists, and their expertise is essential. But sustainability teams cannot deliver organisational transformation alone. The decisions that shape environmental performance happen every day across manufacturing, procurement, engineering, supply chain and executive leadership. A sourcing decision, process improvement, capital investment or technology selection may not be labelled as a sustainability decision, but each influences the organisation’s environmental footprint. The most successful pharmaceutical manufacturers therefore create a culture where sustainability becomes part of operational decision-making rather than an additional approval process. Ownership shifts from one department to the whole organisation. That is when sustainability becomes embedded rather than managed.
Carbon data is shaping decisions, Digital Transformation is becoming essential
Historically, carbon reporting has focused on understanding yesterday. But leadership is about shaping tomorrow. As pharmaceutical organisations mature their sustainability capabilities, carbon data can evolve from a reporting metric into a strategic input. Imagine being able to compare carbon impacts before selecting a supplier, manufacturing process, technology investment or supply chain design. Instead of asking, “What was our footprint?”, leaders can ask, “Which option creates the best commercial and environmental outcome?”. Carbon data becomes significantly more valuable when it informs choices rather than simply measures outcomes.
This evolution is not simply about sustainability, it is also about digital capability. Connected operational data allows organisations to model scenarios, understand trade-offs and evaluate decisions before implementation. Rather than simply producing better reports, digital transformation enables leaders to connect manufacturing and sustainability data, improve Scope 3 visibility, compare sourcing and production options, identify high-impact improvement opportunities and make faster, evidence-based decisions. This is where sustainability, operational excellence and digital transformation increasingly become one conversation.
The pharmaceutical industry has always excelled at solving complex operational challenges through data, process discipline and continuous improvement. Sustainability will be no different. The organisations that lead over the next decade will not simply report their data more accurately; they will make better decisions because they have better insight. They will connect sustainability with manufacturing performance rather than treating it as a separate agenda, and use carbon intelligence to guide future investment rather than simply explain past performance. In the end, the winners in pharma sustainability will not be those with the biggest ESG reports. They will be the organisations that use sustainability insight to build smarter operations, stronger supply chains and better business performance.
